Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederir.exelixis.com
Exelixis, Inc. News Releases
Get the latest updates from Exelixis, Inc. News Releases directly as they happen.
Follow now 113 followers
Latest posts
Last updated 4 days ago
Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
4 days ago
– Conference Call and Webcast to Follow at 5:00 p.m. ET /...
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
20 days ago
– Cabozantinib franchise achieves approximately $2.123 billion in preliminary U.S. net product...
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
24 days ago
– STELLAR-316 will use Natera’s Signatera™ assay to identify MRD-positive patients for...
Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026
25 days ago
– Presentation to be webcast on www.exelixis.com – ALAMEDA, Calif. --(BUSINESS WIRE)--Jan...
Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025
about 2 months ago
- Event to Review R&D Progress and Outline Exelixis’ Strategy for Building...
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
3 months ago
– Presentations to be webcast on www.exelixis.com – ALAMEDA, Calif. --(BUSINESS WIRE)--Nov...
Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update
3 months ago
- Total Revenues of $597.8 million , Cabozantinib Franchise U.S. Net Product...
Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
3 months ago
– Conference Call and Webcast to Follow at 5:00 p.m. ET /...
Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet
3 months ago
– Zanzalintinib in combination with atezolizumab improved median overall survival to 10.9...
Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025
4 months ago
– CABOMETYX reduced the risk of disease progression or death by 81%...
Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development
5 months ago
– Dr. Aftab has served for over 25 years at Exelixis and...
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
5 months ago
– Presentations to be webcast on www.exelixis.com – ALAMEDA, Calif. --(BUSINESS WIRE)--Aug...